Cardiology Activities

Novel Reversal Agents to Safely and Effectively Treat Direct Oral Anticoagulant Bleeding: Education for the Health-System Pharmacist

0290-0000-21-245-H01-P

Apply the most recent evidence-based guidelines to the selection of direct oral anticoagulant (DOAC) reversal agents in reversal of major bleeding associated with the use of DOACs.

1.00

Heart Failure With Reduced and Preserved Ejection Fraction: Optimizing Management and the Pharmacist's Role in Patient Care

0290-0000-21-248-H01-P

This activity will examine ways in which pharmacists can improve their competency in current guideline-directed medical therapy (GDMT), as well as current and emerging treatment options and challenges associated with HFrEF and HFpEF. Such practices can lead to improved clinical decision making for integrating new and emerging therapies for patients with HF, with goals of improving health-related outcomes, reducing hospitalizations, and enhancing the health-related quality of life of patients.

0.75

Current and Emerging Treatment Options to Lower LDL-C in Patients With Statin Intolerance

0290-0000-21-253-H01-P

Review the ongoing burden of cardiovascular disease, current cholesterol guidelines, and issues with statin intolerance

0.75

Discerning Heart Failure: New Treatment Approaches for Preserved or Reduced Ejection Fraction Subtypes

0290-0000-21-201-H01-P

At the completion of this activity, the participant will be able to classify traditional treatments for HFpEF and HFrEF, the lack of medications for HFpEF, and innovative treatment approaches currently in clinical trials.

2.00